| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2003;34:e168.)
© 2003 American Heart Association, Inc.
Research Reports |
1-Antitrypsin in Plasma and Risk of Spontaneous Cervical Artery Dissections
From the Departments of Neurology and Clinical Biochemistry Service (N.R.), University Hospital Germans Trías i Pujol, Badalona, Spain
Correspondence to Nicolás Vila, MD, Neurology Service, University Hospital Germans Trías i Pujol, Carretera de Canyet, 08916, Badalona, Spain. E-mail nvila{at}ns.hugtip.scs.es
| Abstract |
|---|
|
|
|---|
1-Antitrypsin (A1-AT) is a circulating serine proteinase inhibitor of proteolytic enzymes that helps to maintain the integrity of elastic and collagen fibers. Methods To test the hypothesis that moderate deficiency of A1-AT may be a risk factor for sCAD, 22 cases with sCAD and 113 controls were included in the study.
Results Patients with sCAD had significantly mean lower levels of A1-AT compared with controls (116.0±24.9 versus 141.1±31.7 mg/dL; P<0.01). Low levels of A1-AT (<90 mg/dL) were more frequently observed in patients with sCAD compared with controls (27.3% versus 2.7%; P<0.001). A positive correlation between age and plasma levels of A1-AT was found (r=0.22; P<0.01). A1-AT levels were not affected by sex or vascular risk factors, including smoking habit. On multivariate analysis, A1-AT <90 mg/dL was associated with sCAD independently of age, sex, or vascular risk factors (odds ratio, 17.7; 95% confidence interval, 2.9 to 105.6).
Conclusions Low plasma levels of A1-AT may be a risk factor for sCAD.
Key Words: alpha 1-antitrypsin aneurysm, dissecting risk factors
| Introduction |
|---|
|
|
|---|
1-Antitrypsin (A1-AT) is a circulating serine proteinase inhibitor of proteolytic enzymes that contributes to the maintenance of the integrity of connective tissues. Deficiency of A1-AT may result in degradation of the arterial wall through inadequate protection against the proteolytic effect of elastase and collagenase.4,5 A1-AT deficiency is a genetic and systemic disorder characterized not only by lung and liver disease but also by vascular manifestations, including sCAD, fibromuscular dysplasia, or aneurysms.4,5 However, A1-AT deficiency ranges from severe forms with very low circulating levels (10% of normal) in homozygous patients to other forms with moderately low concentrations (60% to 70% of normal) in heterozygous patients.4,5 To evaluate whether moderate deficiency of A1-AT may be a risk factor for sCAD, we performed a prospective case-control study comparing plasma levels of A1-AT in consecutive patients with sCAD and controls.
| Methods |
|---|
|
|
|---|
We recorded demographic data and presence of vascular risk factors. A blood sample was taken at least 2 weeks after stroke onset in cases and controls to avoid the effect of the acute-phase response on plasma protein levels. A1-AT determinations were performed at the hospital laboratory following a standard immune nephelometric technique. Established normal values for A1-AT were between 90 and 200 mg/dL. Levels <90 mg/dL were classified as low; levels
90 mg/dL were classified as normal. The study was approved by the local ethics committee.
For statistical bivariate analysis,
2 test, Students t test, or the Mann-Whitney test was used as appropriate. Pearsons correlation coefficient analyzed the association between continuous variables. The relation between low levels of A1-AT and sCAD was assessed by logistic regression analysis, entering into the model all variables with values of P<0.1 on bivariate testing, including age, risk factors, and A1-AT <90 mg/dL. Odds ratios and 95% confidence intervals were calculated from ß coefficients and their SE. A value of P<0.05 was established as statistically significant.
| Results |
|---|
|
|
|---|
|
|
| Discussion |
|---|
|
|
|---|
In this study, we detected that 1 of every 3 patients with sCAD had reduced levels of A1-AT. Because blood determinations were done after the effects of the acute phase of stroke, we speculate that levels of A1-AT detected in plasma reflect genetically determined activity. We could not correlate protease inhibitor (PI) phenotypes with A1-AT levels because only a few sCAD patients had these determinations. However, our results are in the same direction as previous case reports in which an association between deficient protease inhibitor phenotypes (PIZ and PIS) of A1-AT and the presence of sCAD was observed.4,5,7,8
An association between age and A1-AT levels was found in all subjects, suggesting that levels of A1-AT, like other acute-phase proteins, increase with age. Because sCAD cases were younger than controls, it is possible to speculate that low levels of A1-AT in sCAD reflect their younger age. However, low levels of A1-AT remained in the predictive multivariate model of sCAD as a risk factor independently of age. Cigarette smoking decreases the efficacy of A1-AT, resulting in a situation similar to the genetically determined A1-AT deficiency.9 In this study, we did not find different levels of A1-AT according to smoking habit, and low levels of A1-AT remained independently associated with sCAD when smoking was entered into the model.
In conclusion, this study suggests that low plasma levels of A1-AT may be a risk factor for sCAD.
| Acknowledgments |
|---|
Received January 10, 2003; revision received April 15, 2003; accepted April 29, 2003.
| References |
|---|
|
|
|---|
2. Brandt T, Hausser I, Orbeck E, Grau A, Hartschuh W, Anton-Lamprecht I, Hacke W. Ultrastructural connective tissue abnormalities in patients with spontaneous cervicocerebral artery dissections. Ann Neurol. 1998; 44: 281285.[CrossRef][Medline] [Order article via Infotrieve]
3. Pezzini A, Del Zotto E, Archetti S, Negrini R, Bani P, Albertini A, Grassi M, Assanelli D, Gasparotti R, Vignolo LA, et al. Plasma homocysteine concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissections and atherothrombotic stroke. Stroke. 2002; 33: 664669.
4. Schievink WI, Prakash UB, Piepgras DG, Mokri B. Alpha 1-antitrypsin deficiency in intracranial aneurysms and cervical artery dissection. Lancet. 1994; 343: 452453.[CrossRef][Medline] [Order article via Infotrieve]
5. Schievink WI, Katzmann J, Piepgras DG. Alpha-1-antitrypsin deficiency in spontaneous intracranial arterial dissections. Cerebrovasc Dis. 1998; 8: 4244.[CrossRef][Medline] [Order article via Infotrieve]
6. Tsujii T, Katayama K, Naito I, Seno S. The circulating alpha-antitrypsin-elastase complex attacks the elastic lamina of blood vessels: an immunohistochemical study. Histochemistry. 1988; 88: 443451.[CrossRef][Medline] [Order article via Infotrieve]
7. Plaschke M, Auer D, Trapp T, Trenkwalder P, Trenkwalder C. Severe spontaneous carotid artery dissection and multiple aneurysmal dilatations: a case report. Angiology. 1996; 47: 919923.[Medline] [Order article via Infotrieve]
8. Pezzini A, Magoni M, Corda L, Pini L, Medicina D, Crispino M, Pavia M, Padovani A, Grassi V. Alpha-1-antitrypsin deficiency-associated cervical artery dissection: report of three cases. Eur Neurol. 2002; 47: 201204.[CrossRef][Medline] [Order article via Infotrieve]
9. Laurent P, Bieth JG. Cigarette smoke decreases the rate constant for the association of elastase with alpha-1 proteinase inhibitor by a non-oxidant mechanism. Biochem Biophys Res Commun. 1985; 126: 275281.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
C. Grond-Ginsbach, S. Engelter, I. Werner, I. Hausser, U. S. Muller, T. Brandt, and P. Lyrer Alpha-1-antitrypsin deficiency alleles are not associated with cervical artery dissections Neurology, April 13, 2004; 62(7): 1190 - 1192. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |